Fitting a Drug-Inhibited Precursor Formation Model

Why Fit the Precursor and Product Together?

When a drug inhibits precursor formation, the precursor pool responds first. A downstream product may change later because it depends on the precursor available for conversion as well as on its own removal. Fitting both time courses can therefore usefully constrain a proposed mechanism: a model must account for the timing and magnitude of both responses, not just the product’s eventual change.

The model below assumes that the drug concentration profile \(C(t)\) is available as an input. It represents drug action as inhibition of precursor formation, while precursor loss, precursor-to-product conversion, and product loss follow first-order kinetics. The purpose of fitting is to find parameter values that describe the observed time courses under these assumptions, then evaluate how well those values are supported by the data.

This definition assumes the drug affects precursor formation, not the loss of precursor or product. It also assumes first-order loss and conversion, a stable parameter set over the fitted period, and no other unmodeled input or pathway that materially changes either pool. The inhibition term is bounded between zero and \(I_{\max}\); at \(C=0\), formation is uninhibited, and as \(C\) becomes large, the inhibited fraction approaches \(I_{\max}\).

Baseline Values and the Model’s Implications

If the system is at a stable baseline before drug exposure, set \(C=0\) and both time derivatives to zero. The precursor’s baseline concentration \(P_0\) and the product’s baseline concentration \(B_0\) then satisfy

These equalities are useful for initializing a fit, but they are conditional: they hold only if baseline is at steady state and the equations adequately represent baseline biology. If baseline concentrations are measured, one can estimate the formation rate as \(k_{\mathrm{in},P}=k_P P_0\), and estimate \(k_{PB}=k_BB_0/P_0\) when the other quantities are known. Alternatively, fit baseline concentrations and kinetic parameters jointly, while recognizing that this adds dependence between estimated quantities.

A common parameterization uses \(P_0\), \(B_0\), and the turnover rate constants directly. The baseline relationships then define \(k_{\mathrm{in},P}=k_PP_0\) and \(k_{PB}=k_BB_0/P_0\). This can keep parameters interpretable and make the model’s baseline constraints explicit. It does not remove the need to check whether the observations actually support each parameter.

Fitting the Linked Time Courses

For each observation time, the model predicts \(P(t)\) and \(B(t)\) by solving the differential equations with the measured or otherwise specified \(C(t)\). Fit parameters by comparing those predictions with observations. A simple error model assumes independent, normally distributed additive errors with constant standard deviation for each analyte. Under that assumption, minimizing a weighted sum of squared residuals is equivalent to maximizing the likelihood:

Here \(\theta\) collects the model parameters, \(P_i\) and \(B_j\) are observed concentrations, the hatted values are model predictions at their respective observation times, and \(\sigma_P,\sigma_B\) are residual standard deviations. The weighting prevents an analyte with larger numerical values or units from automatically dominating the fit. If error variability increases with concentration, a proportional or combined error model may be more appropriate; the residual assumptions should reflect the measurement process rather than convenience.

Initial conditions are part of the model, not a cosmetic setting. Use measured pretreatment concentrations when available. If steady state is defensible, baseline constraints can link initial conditions to rate parameters. If concentrations are changing before dosing, imposing steady state can force the drug-effect parameters to compensate for baseline drift. In that case, a fit may look numerically successful but yield misleading parameter estimates.

Exposure, Inhibition, and Delayed Product Response

At a fixed concentration \(C\), the fraction of precursor formation inhibited is \(I_{\max}C/(IC_{50}+C)\). The eventual precursor concentration under constant exposure is therefore \(P_{\mathrm{ss}}=P_0[1-I_{\max}C/(IC_{50}+C)]\), provided the same steady-state assumptions apply. The product’s eventual concentration is \(B_{\mathrm{ss}}=k_{PB}P_{\mathrm{ss}}/k_B\). These equilibrium relationships do not say how quickly either pool approaches its new level; the differential equations determine that timing.

A short derivation illustrates why the product can lag. Under constant exposure, write \(u=1-I_{\max}C/(IC_{50}+C)\). Then \(dP/dt=k_{\mathrm{in},P}u-k_PP\), a first-order equation with solution \(P(t)=P_{\mathrm{ss}}+[P(0)-P_{\mathrm{ss}}]e^{-k_Pt}\), where \(P_{\mathrm{ss}}=k_{\mathrm{in},P}u/k_P\). The product follows \(dB/dt+k_BB=k_{PB}P(t)\); it responds to the changing precursor rather than directly to the drug concentration. Thus the product trajectory depends on both precursor and product turnover, and a late or modest product response does not by itself demonstrate weak inhibition.

Uncertainty Checks and Failure Modes

A point estimate alone is not enough. Local standard errors or confidence intervals can summarize uncertainty when the likelihood is well behaved near its optimum, but they can be unreliable near parameter bounds, with strong parameter correlations, or when the likelihood is asymmetric. Profile likelihood or resampling can provide useful checks when those conditions are doubtful. In particular, \(I_{\max}\) and \(IC_{50}\) may be difficult to distinguish if the observed concentrations cover only a narrow range: the data may show an effect without establishing both its maximum and its concentration dependence.

Diagnostics should include time-course predictions and residuals for each analyte. Residuals that change sign systematically over time, repeated underprediction of the product’s early decline, or a delayed rebound not captured by predictions can indicate a structural mismatch. Residual spread that increases with fitted concentration challenges a constant-variance error assumption. Also check numerical integration and parameter constraints: a solver failure or boundary estimate may reflect computation or inadequate data, not a biological zero effect.

The main alternative explanations should be kept distinct. A direct drug effect on product formation or loss changes a different model component than inhibition of precursor formation. An explicit precursor pool is also not interchangeable with a direct effect on the product simply because both can produce delay. The fit to both measured time courses, exposure coverage, parameter uncertainty, and residual structure help assess whether the proposed mechanism is credible; they do not establish causation or rule out every alternative.

Common Pitfall and Practical Limits

Wrong reasoning: “The product concentration barely changes just after dosing, so the fitted maximum inhibition must be near zero.” This ignores the product balance at the starting time: its formation and removal can still be equal while the precursor is already falling. Correction: interpret the initial derivatives and the linked equations together, and use observations over time to distinguish immediate precursor effects from downstream response.

The model is limited when baseline is not stable, precursor or product is measured with substantial error, the exposure profile is poorly observed, or the inhibition curve is sampled only on one side of \(IC_{50}\). Its parameter estimates are conditional on the chosen pathways and error model. A good numerical fit is therefore necessary but not sufficient: the predictions, residuals, constraints, and uncertainty must also be compatible with the data and assumptions.